Johns Hopkins: Blood Transfusions Overused During Surgery
Researches examined the records of 2,981 patients who received blood transfusions during surgery at Johns Hopkins between February 2010 and August 2011. According to the researchers, surgeons can safely wait until a patient's hemoglobin levels fall to 7 or 8 grams per deciliter, but many patients in the study undergoing surgery for pancreatic cancer, orthopedic problems and aortic aneurysms received a transfusion at 10 grams per deciliter or above.
Overusing blood transfusions is expensive. The researchers note that while unit of blood can cost a hospital up to $1,100, Medicare reimbursement is only $182 for that unit, exposing an opportunity for cost savings by more carefully controlling blood transfusions, according to a news release.
Unnecessary blood transfusions are also dangerous. Blood transfusions suppress a patient's immune system, and often patients develop antibodies to transfused red blood cells, making a donor match harder to find should a transfusion be needed in the future, according to the news release.
More Articles on Surgical Quality:North Shore-LIJ Introduces Video Auditing of Surgical Time Outs
Study: High Surgical Volume Positively Affects Outcomes
Study: Beta Blockers Associated With Lower Mortality in High-Risk Surgery Patients
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- UnitedHealthcare now posts Healthgrades star ratings for each physician: 7 key notes
- Joint Commission: New tools for medical error prevention
- Mederi Therapeutics launches 3rd generation of Stretta, Boston Scientific reports Q1 2016 financials & more — 5 GI company key notes
- Gastroenterologist pay in the US, UK, Canada & Australia: 5 notes
- Seres Therapeutics signs research agreements to support development of microbiome therapy for IBD: 3 points